Mankind Pharma Exits Non-Core Hospitality Business

Mankind Pharma Limited has completed the 100% divestment of its stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP for a cash consideration of ₹49 crore, effective August 31, 2026. Key Highlights: Minimal Financial Impact: The divested entity contributed only ₹9.63 crore (0.07%) to FY26 revenue and held a net worth of ₹38.99 crore (0.24% of Mankind’s total), making this a highly immaterial transaction for the parent company's financials. Complete Exit: Broadway Hospitality ceases to be a subsidiary, marking Mankind Pharma's total withdrawal from the non-core leisure and hospitality sector. Strategic Rationale: Portfolio Rationalization: This move aligns with management’s stated strategy to shed peripheral assets and sharpen the company's focus on high-margin pharmaceutical manufacturing, R&D, and core healthcare operations. Management Bandwidth: The operational cleanup frees up management focus and capital, which is currently critical for the seamless integration of recent large-scale strategic acquisitions, such as Bharat Serums and Vaccines. Outlook: This divestment is a clean, positive step for corporate governance and capital allocation. By eliminating non-core business lines, Mankind Pharma reinforces its identity as a pure-play pharmaceutical major, optimizing its corporate structure for sustained, focused growth in the domestic and global healthcare markets.